Navigation Links
Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
Date:5/9/2013

SEATTLE, May 9, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. 

(Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO)

Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response. The immunoSEQ assay uses high throughput next-generation sequencing to characterize the repertoire of T and B cell receptors.  Application of this technology is being explored in cells of cancer patients, to assess the impact of treatments on the immune system and evaluated as a tool to identify patient populations who might be more likely to respond to targeted therapies based on their immune status.

"We are delighted to collaborate with Bristol-Myers Squibb to help uncover immunological biomarkers of response to cancer agents," said Chad Robins , CEO and Founder of Adaptive Biotechnologies.  "Collaborating with Bristol-Myers Squibb is a real win for companies like ours that are committed to deepening the understanding of the interaction between the host immune system and the cancer cells themselves."

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company's core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research and clinical communities as well as the biopharmaceutical industry. Adaptive operates a state-of-the-art high throughput centralized laboratory in Seattle that is CLIA certified and will be accepting clinical samples in 2013. Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system's defense against disease – with unprecedented depth and specificity. In 2013, the company will introduce clonoSEQ (http://www.clonoseq.com), a clinical assay to measure and monitor minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today's most common tests. All of Adaptive Biotechnologies' assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface.


'/>"/>
SOURCE Adaptive Biotechnologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
2. TriLink BioTechnologies Awards Keck Science Department ResearchReward
3. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
4. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
5. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
6. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
7. Vestiage Signs Buyside Engagement Agreement with CJK Securities
8. Vertilon Signs Crisel Instruments as its Distributor in Italy
9. Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine
10. Entertainment Agency and Speaker Bureau Mark Sonder Productions Signs the Health & Wellness Shaman, Robert Cohen, PhD, LPC, DCEP for Meetings and Events Worldwide
11. Samsung Thales signs Development Agreement with Novelda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, ... Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 ... for preclinical and clinical safety programs. “We’ve seen significant demand for, and we ...
(Date:5/18/2016)... 2016 The Biotech industry continues to ... that there are no opportunities ahead. Today, ActiveWallSt.com has on ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ... Corp. (NASDAQ: OPHT ). Sign up now to ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained ...
(Date:5/17/2016)... -- Haselmeier announces the launch by Merck ... EMA, the European Medicines Agency. Originally launched in 2011 ... new pen version includes enhancements to further improve the ... patients during use. Its enhanced design has ... with a larger display window that improves the readability ...
(Date:5/17/2016)... BASEL, Switzerland , May 17, 2016 /PRNewswire/ ... sciences company located in Basel, Switzerland ... an investigational oral inhibitor of P38 mitogen-activated protein ... ) , Strekin will build the ... Pamapimod in indications in which MAP Kinases play ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):